House Energy and Commerce Committee leaders yesterday sent letters to nine contract pharmacies that participate in the 340B drug savings program requesting information about their participation in the program. The letters sought information on contracting practices; the distance between covered entities and contract pharmacies; to what degree contract pharmacies prevent duplicate discounts or diversion in the program; and whether contract pharmacies ensure low-income uninsured patients do not face high drug costs despite the program’s discount. The letters follow a June Government Accountability Office report recommending that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B requirements.
 

Related News Articles

Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.“It is a ‘solution’ in search of a…